All In Biotech

Drug Trial Radar · NCT00364858

Safety and Efficacy of Cerezyme® Infusions Every 4 Weeks Versus Every 2 Weeks in Type 1 Gaucher Disease

A Phase IV, Multicenter, Randomized, Dose Frequency Study of the Safety and Efficacy of Cerezyme® Infusions Every Four Weeks Versus Every Two Weeks in the Maintenance Therapy of Patients With Type 1 Gaucher Disease

Last checked: Nov 19, 2026Latest source record: Apr 3, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

95

Actual

Start

Dec 2001

Primary completion

Not stated

Study completion Feb 2007

Sponsor

Lead sponsor
Genzyme, a Sanofi CompanySanofi (SNY)
Sponsor type
Industry
First posted
Aug 16, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized trial to compare the safety and efficacy of two dosing frequencies of Cerezyme® in patients with Gaucher disease who are currently being treated with Cerezyme®. Approximately 90 patients will be randomized in a 2:1 (q4 : q2) ratio to one of two treatment arms at up to 26 study centers worldwide. Patients will continue to receive the same total 4-week dose that they were receiving prior to study enrollment, however, they will be randomized to receive either their total 4-week dose in two infusions, one infusion every 2 weeks or their total 4-week dose in one infusion every 4 weeks. The randomization scheme will ensure a 2:1 balance between the every 4-week versus every 2-week infusion groups, respectively.

Conditions

  • Gaucher Disease, Type 1
  • Cerebroside Lipidosis Syndrome
  • Glucocerebrosidase Deficiency Disease
  • Glucosylceramide Beta-Glucosidase Deficiency Disease
  • Gaucher Disease, Non-Neuronopathic Form

Interventions

  • CerezymeDrug

    Cerezyme doses of 20-60U/kg every 2 weeks (Q2 Arm) or 40-120 U/kg every 4 weeks (Q4 Arm).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Clinical Success at Month 24/DiscontinuationTime frame: Month 24 (or at time of discontinuation)

Locations

26 sites in 7 countries. Site status is shown where the registry gives one.

  • Children's National Medical Center

    Washington D.C., District of Columbia

  • University Research Foundation for Lysosomal Storage Disease, Inc.

    Coral Springs, Florida

  • Emory University

    Atlanta, Georgia

  • Children's Memorial Hospital

    Chicago, Illinois

  • Midwest Cancer Research Group, Inc.

    Skokie, Illinois

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Institute for Genetics Medicine Saint Peter's University Hospital

    New Brunswick, New Jersey

  • Holy Name Hospital

    Teaneck, New Jersey

  • Hemophilia Center of Western New York

    Buffalo, New York

  • New York Oncology/Hematology PC

    Latham, New York

  • New York University

    New York, New York

  • Mt. Sinai Medical Center

    New York, New York

  • Duke University Medical Center

    Durham, North Carolina

  • Children's Hospital Research Foundation

    Cincinnati, Ohio

  • Oregon Health & Science University

    Portland, Oregon

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania

  • University of Pittsburgh

    Pittsburgh, Pennsylvania

  • University of Utah

    Salt Lake City, Utah

  • Estadual de Hematologia Arthur de Siqueira Cavalcanti (HEMORIO)

    Rio de Janeiro, Brazil

  • Mount Sinai Hospital

    Toronto, Ontario, Canada

  • Istituto Giannina Gaslini

    Genova, Italy

  • Universita degli Studi di Napoli "Federico II"

    Naples, Italy

  • Istituto per l'Infanzia Burlo-Garofolo

    Trieste, Italy

  • Instytut Pomnik Centrum Zdrowia Dzeicka

    Warsaw, Poland

  • Hospital Vall d´Hebrón

    Barcelona, Spain

  • Royal Free Hospital

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.